SELECT * FROM `stock_list` WHERE `symbol` = "MVRBF" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='MVRBF' AND exchange = 'OTCPK' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "MVRBF" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 MVRBF (Medivir AB) Equity-to-Asset
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Equity-to-Asset

Medivir AB (Medivir AB) Equity-to-Asset : 0.76 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Medivir AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medivir AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $21.25 Mil. Medivir AB's Total Assets for the quarter that ended in Dec. 2023 was $28.07 Mil. Therefore, Medivir AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.76.

The historical rank and industry rank for Medivir AB's Equity-to-Asset or its related term are showing as below:

MVRBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.63   Med: 0.83   Max: 0.91
Current: 0.76

During the past 13 years, the highest Equity to Asset Ratio of Medivir AB was 0.91. The lowest was 0.63. And the median was 0.83.

MVRBF's Equity-to-Asset is ranked better than
61.64% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs MVRBF: 0.76

Medivir AB Equity-to-Asset Historical Data

The historical data trend for Medivir AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Equity-to-Asset Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.74 0.84 0.82 0.76

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.80 0.74 0.71 0.76

Competitive Comparison of Medivir AB's Equity-to-Asset

For the Biotechnology subindustry, Medivir AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Medivir AB's Equity-to-Asset falls into.



Medivir AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Medivir AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=21.245/28.068
=0.76

Medivir AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=21.245/28.068
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB  (OTCPK:MVRBF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Medivir AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Medivir AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.